STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, CBNK
NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
- Doma Holdings, Inc. (NYSE: DOMA), relating to its proposed sale to Title Resources Group. Under the terms of the agreement, DOMA shareholders are expected to receive $6.29 in cash per share they own. Click here for more information: https://monteverdelaw.com/case/doma-holdings-inc/. It is free and there is no cost or obligation to you.
- Landos Biopharma, Inc. (NASDAQ: LABP), relating to its proposed sale to AbbVie, Inc. Under the terms of the agreement, LABP shareholders are expected to receive $20.42 in cash plus one non-tradable CVR worth up to $11.14 per share they own. Click here for more information: https://monteverdelaw.com/case/landos-biopharma-inc/. It is free and there is no cost or obligation to you.
- Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, FUSN shareholders are expected to receive $21.00 in cash plus one non-tradable CVR worth up to $3.00 per share they own. Click here for more information: https://monteverdelaw.com/case/fusion-pharmaceuticals-inc/. It is free and there is no cost or obligation to you.
- Capital Bancorp, Inc. (Nasdaq: CBNK), relating to its proposed merger with Integrated Financial Holdings, Inc. Under the terms of the agreement, CBNK shareholders are estimated to receive $5.36 in cash and 1.115 shares of Capital common stock per share they own. Click here for more information: https://monteverdelaw.com/case/capital-bancorp-inc/. It is free and there is no cost or obligation to you.
About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track